Needham Sees Buying Opportunity in This Penny Stock

GERN stock has more than doubled off its December lows

Apr 9, 2019 at 10:08 AM
facebook twitter linkedin

Geron Corporation (NASDAQ:GERN) stock is red-hot today, after Needham upgraded the cancer specialist to "buy" from "hold, and assigned a $3 price target -- a 63% premium to last night's close. The brokerage firm said the "negative optics of a big pharma passing on imetelstat" creates a buying opportunity for the penny stock. This comes after Johnson & Johnson (JNJ) subsidiary Janssen terminated its imetelstat collaboration with Geron last September.

In reaction, GERN stock is up 3.2% at $1.90, pacing toward its sixth straight win. Since bottoming below the $1 level in late December, the shares have more than doubled, but have struggled against the $2 mark -- near a massive Sept. 27 bear gap.

Analysts are optimistic, with all three in coverage maintaining a "buy" or better rating on GERN. Plus, the average 12-month price target sits all the way up at $3.63.

Short sellers, on the other hand, have heavily targeted GERN. The 41.09 million shares currently sold short represents 22% of the stock's available float, or 10.1 times the average daily pace of trading.




These investors are using the market's volatility to their advantage and scoring triple-digit gains on many of their trades.

Even in today's sideways bear market, this trading strategy has continued to provide consistency and profitability to a small group of investors. By using this approach, these traders are removing directional risk and still hitting triple-digit returns. If you want access to this strategy, and lower risk with higher returns sounds good to you, then don't wait another minute.

Join us now to receive our next trades the moment they come out!


Common mistakes options traders make


Special Offers from Schaeffer's Trading Partners